By Fineline Cube 
Sino-US firm Sepax Technologies Co., Inc. has successfully completed its initial public offering (IPO) on the Shanghai Stock Exchange’s Sci-Tech Innovation Board (STAR). The opening price of RMB 28.15 per share marked a significant increase of 551% from the issue price of RMB 4.32. The final closing price settled at RMB 20.7, reflecting an increase of 379.2%, with the total market value reaching RMB 8.621 billion.
Company Overview and Core Products
Sepax Technologies is a leading company focused on the development and manufacturing of liquid chromatography materials for the separation and purification of biomolecules and other drugs. The company’s core products include chromatography medium and liquid chromatography columns, which are widely applied across R&D, manufacturing, and quality control of antibodies, antibody drug conjugates (ADCs), GLP-1, recombinant proteins, vaccines, and other biologic drugs.
Backers and Financial Support
Sepax Technologies has received significant financial support from prominent investors. Notably, China-based Gan & Lee Pharmaceuticals (SHA: 603087) participated as one of the backers in the Series D financing round, highlighting the company’s strong industry connections and financial backing.
Future Prospects
The successful IPO on the STAR market represents a significant milestone for Sepax Technologies, providing the company with additional capital to expand its operations and accelerate product development. With its core products and strong market position, Sepax is well-positioned to capitalize on the growing demand for advanced biologic drug manufacturing technologies.-Fineline Info & Tech